CD137
阿替唑单抗
兴奋剂
抗体
癌症研究
医学
免疫系统
免疫疗法
受体
免疫学
内科学
无容量
出处
期刊:Cancer Discovery
[American Association for Cancer Research]
日期:2023-06-05
卷期号:13 (8): OF2-OF2
标识
DOI:10.1158/2159-8290.cd-nb2023-0044
摘要
Abstract Findings from a phase I study of the bispecific antibody RO7122290, which targets CD137 and the fibroblast activity protein, show that it produces responses in patients with advanced solid tumors—without the liver toxicity associated with earlier therapies targeting CD137. Additional research evaluating RO7122290 in combination with atezolizumab or other immune agents is planned.
科研通智能强力驱动
Strongly Powered by AbleSci AI